Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments.

Expect to hear critical insights from leading biopharma, oncologists and diagnostic providers to utilise liquid biopsies as surrogate endpoints in clinical trials, guide dosing decisions and enable the development of precise drugs for patients with unmet needs in oncology and beyond.

Join your peers from Biomarker, Translational and Clinical Development teams to more accurately monitor drug response through MRD assessments for improved treatment regimens from early to late stage clinical trials to improve patient outcomes.

This event is free to attend* if you work for a drug developer, researcher, or academic institution.

Download the event guide for full details: https://ter.li/ig2qtr

*View the website for full T&Cs: https://ter.li/h7ri3w